Home / Markets / Industries / Health Care
Tuesday, October 07, 2008
MonoGen, Inc. Announces Cessation of Commercial Operations
Comtex
LINCOLNSHIRE, ILLINOIS, Oct 07, 2008 (MARKET WIRE via COMTEX) ----MonoGen, Inc. (TSX: MOG) has today announced both the cessation of active commercial operations and a corresponding reduction of approximately 75% of its workforce, effective immediately.
Ted S. Geiselman, MonoGen's President and CEO, commented, "It is with great disappointment that we find it necessary to take this strong action at this time. Despite our significant and thorough efforts seeking additional investment capital, adverse financial market conditions in conjunction with increased challenges on the commercial front have made raising additional capital unfeasible. As a result, we feel that in order to better serve MonoGen shareholders, creditors, employees and other stakeholders we must seek to identify additional alternatives for the support of our continued new product development efforts as well as the commercial activities associated with the MonoPrep System, perhaps through a sale of the company or its assets."
Mr. Geiselman continued, "To that end, we have engaged Piper Jaffray, a well known and respected investment bank serving the life sciences industry, to immediately help us begin the process of identifying our strategic and financial alternatives. Obviously our objective will be to obtain the greatest value possible from the significant technology MonoGen has developed. We feel our MonoPrep System and our MonoPrep imaging system, currently under development, represent important and compelling advancements in liquid-based cytology technology."
The company will provide additional information as it becomes available.
About MonoGen, Inc.
MonoGen, Inc., headquartered in the Chicago area, is a medical device and diagnostics company providing high-quality and cost-effective cytological screening and diagnostic products to healthcare providers in the anatomic pathology industry.
Forward-Looking Statements
Statements contained in this press release relating to matters that are not historical facts are forward-looking statements. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements. Forward-looking statements are based on our beliefs and assumptions based on information available at the time the assumptions were made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause our actual results to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to, our ability to raise additional capital, our ability to execute our business plan while maintaining at all times our various regulatory approvals, and the response from existing and potential competitors. Additional discussions of the various risks are contained in our Annual Information Form dated March 19, 2008, which is available on SEDAR (www.sedar.com). Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document.
Contacts: MonoGen investor relations 847-758-4284 Gordon K. Johnson Managing Director Piper Jaffray 212-284-9593
SOURCE: MonoGen, Inc.
Copyright 2008 Market Wire, All rights reserved.
FOX Translator
No data currently available.
No data currently available.
Some mutual funds want you to pay for the privilege of them (or your investment adviser) taking your money to invest. It's called a load, and it works like a cover charge to get into a nightclub. Luckily, there are such things as no-load funds. As the name implies, shares of these funds are sold without a fee paid to a broker or investment advisor.
The entire amount you invest in no-load funds goes to work for your returns. On the other hand, with load funds, right off the bat you're charged commission (not to mention other fees incurred over the life of the investment). Let's say, for example, you invest $25,000 into a load fund that charges a 5% commission. This costs you $1,250 off the top, bringing your actual investment down to only $23,750.
The often-cited horse race analogy argues against investing in load funds. Here's the logic behind it: Would you place a bet on a horse that had to start a race 200 yards behind the others? Well, maybe you would if you got a tip from a sketchy, trench coat-clad man in a dark alley. However, under most circumstances, it's not smart to put your money on that handicapped horse.
But some argue that at times that man in the trench coat (aka your broker) knows more about the horses than you do, and has a better shot at picking a winner. Also, sometimes these fees are unavoidable because some funds are available only through investment advisers.
Cost-benefit analysis can help determine when a load fund is worth it (in other words, when it will score you a load) and when it is better to "do it yourself" and avoid the fees. Load-fund fees range depending on share class and can cover a variety of costs, such as paper work and fund management.
